Description

Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).

Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).

---

Transfection Reagent for SK-N-SH Cells (Neuroblastoma Cells, HTB-11)

• Proprietary cationic lipids formulation
• High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
• A proven reagent for establishing stable cell lines
• Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
• Download in vitro SK-N-SH transfection protocol: [PDF]
• Download SK-N-SH CRISPR/Cas9 transfection protocol: [PDF]
• Download PowerPoint presentation for SK-N-SH cells transfection kit: [PPT]
• Developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 81% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems SK-N-SH Transfection Protocol: [PDF]

Download MSDS: [PDF]

SK-N-SH Cell Line:

Pediatric brain tumors are considered the leading cause of cancer-related deaths in children, despite new brain cancer treatments and therapies that are implemented every year. The vast majority of brain cancers are highly invasive and predict poor prognosis; therefore, innovative immunotherapy treatment options are desperately needed. Established cell lines are valuable preclinical models for brain cancer research that provide scientists with a better understanding of the biology of the disease and could lead to the development of brain cancer therapeutics. The SK-N-SH cell line was isolated by J.L. Biedler in 1970 from brain tissue of a 4-year-old female patient during a bone marrow biopsy of a metastatic neuroblastoma.  SK-N-SH cells make for a good transfection host and show a higher doubling time as well as higher levels of dopamine-beta-hydroxylase production. The modal chromosome number of this cell line is 47. SH-SY5Y is a triple-cloned neuroblastoma, which originated in 1978 from the SK-N-SH line. A neuroblast-like subclone of SK-N-SH was named SH-SY. The SH-SY cell line was subcloned as SH-SY5 and was subcloned one more time as SH-SY5Y. This cell line is genetically female, with two X chromosomes. SH-SY5Y possess an abnormal chromosome called trisomy 1q. The cell line has been shown to be acetylcholinergic, glutamatergic and adenosinergic as well as dopamine beta-hydroxylase active. SH-SY5Y propagate through mitosis and differentiate by extending neurites to the surrounding area. The cells can form clusters of cells that remind of their malignant nature. However, different treatments, including retinoic acid and brain-derived neurotrophic factor, can make the cells to dendrify and differentiate. It has been shown that citrus limonoid glucosides can be toxic to SH-SY5Y cancer cells. The SK-N-SH neuroblastoma cell line exhibits neurite outgrowths through modulated differentiation, which makes these cells very useful in the study of neural pathways. Altogen Biosystems provides lipid-based transfection kits for the SK-N-SH cell line.

Data:

Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into SKNSH cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).

Figure 2. Protein expression of Lamin A in SK-N-SH cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into SK-N-SH cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):

• 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
• Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model … Lyzogubov et al [PDF]
• Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
• Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]
• 2012 59(1):158-66. Role of uncoupled endothelial nitric oxide synthase … Gao et al [PDF]
• Jounal of Biological Chemistry. 2012 287(4):2907. Chaperoning of mutant p53 protein … Gogna et al [PDF]
• PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
• J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
• 2011 141(2) Differential type I interferon-mediated autophagic trafficking … Desai et al [PDF]
• PLoS Pathog. 2014 10(10) Exosomes from hepatitis C infected patients transmit HCV … Bukong et al [PDF]

Altogen Biosystems:
Altogen Biosystems manufacturers preoptimized transfection kits for cancer research. Reagents and transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery into liver, pancreas, and kidney tissues), and in vivo biodistribution reagents (PEG-Liposome, Nanoparticle, Lipid, and Polymer-based kits). Optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, and RNA molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

• 0.5 ml (Catalog #6915)
• 1.5 ml (Catalog #6916)
• 1.5 ml CRISPR (Catalog #2196)
• 8.0 ml (Catalog #7088)

Altogen生命科学公司致力于研发，生产和销售特定细胞系的转染试剂，用于细胞间生物分子的传递，并通过对转染试剂类型的设计将siRNA和质粒DNA有效地转入不同的细胞系和原代细胞内。 Altogen公司开发的聚合物，脂质体，纳米粒子为基础的转染技术分别针对分子生物学，组合化学，和细胞生物学而分别应用。 Altogen定制服务提供符合GLP要求定制研究服务，包括代稳定的细胞系，细胞银行和冷冻保存，焦磷酸测序，克隆，RNA干扰（RNAi）和基因沉默服务，发展分析，siRNA文库筛选，并转染服务。稳定的肿瘤细胞株和原代细胞的产生，可以是非常昂贵和费时。该公司的细胞培养科学家的细胞株的选择，无论是利息或shRNA表达载体的稳定表达的基因改造。标准的RNAi技术服务，包括设计与合成的siRNA的利益，验证siRNA的沉默效率，siRNA转染条件的优化，使高效的基因沉默细胞系或原代培养细胞的靶基因。 转染培养细胞的瞬时或稳定的引入外源性分子和遗传物质（即RNA或DNA），通常是在生物实验室用来研究基因功能，基因表达的调节，生化映射，突变分析，和蛋白质的生产。科学家利用各种载体分子，这种分子，使质粒DNA（PDNA），信使RNA（mRNA），短干扰RNA（siRNA），小分子RNA（miRNA）的，并进入肿瘤细胞株和原代细胞的蛋白质的基因交付。不幸的是，无单提货的方法或转染试剂，可以适用于所有类型的细胞，细胞的细胞毒性和转染效率显着不同，取决于试剂，协议，并正在利用细胞类型。 Altogen生物系统公司提供超过60种类型的细胞的预优化转染试剂盒。 纳米粒子，脂质和聚合物基ALTOGEN ®在体内转染试剂，使交付功能的RNA和DNA分子在体内。 PEG脂质体在体内输送系统减少由于PEG修饰的先天免疫反应，并提供高效的siRNA转染的DNA，并在体内的蛋白质。 由科学“杂志（2010年12月17日）：PEG脂质体在体内转染试剂盒siRNA的特色 Altogen生物系统功能的特定细胞系转染试剂盒：   公司：www.altogen.com